Federated Hermes’s Opus Genetics IRD Stock Holding History

Federated Hermes’s Portfolio IRD Stock Details IRD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-192	Closed	-$833	–	2217
2023 Q2	$833	Buy	+192	New	+$912	﹤0.01%	2033

Other funds holding IRD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

MCM

MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return

Richmond Brothers Jackson, Michigan $150M AUM 14.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

Diametric Capital Boston, Massachusetts $385M AUM 31.69% 1-Year Est. Return

Federated Hermes's IRD Position: Q3 2023 in Review

Federated Hermes sold out of Opus Genetics (IRD) in Q3 2023, closing a stake of 192 shares — an estimated $833 sold.

Federated Hermes first reported a position in IRD in Q2 2023 and held it in 1 quarter. The position peaked at $833 in Q2 2023. 49 funds tracked by Wall St. Rank hold IRD as of Q3 2023.

Federated Hermes reported no remaining Opus Genetics position as of Q3 2023 after selling out during the quarter.
Federated Hermes sold 192 Opus Genetics shares in Q3 2023, an estimated $833.
Federated Hermes first reported a position in Opus Genetics in Q2 2023 and held it in 1 quarter.
Federated Hermes's Opus Genetics position peaked at $833 in Q2 2023.
49 funds tracked by Wall St. Rank held Opus Genetics as of Q3 2023.

Based on Federated Hermes's 13F filing for Q3 2023, filed 13 Nov 2023.